Navigation Links
Sitagliptin, Under Investigation For Type 2 Diabetes

The number of people suffering from diabetes is already over 194 million worldwide and the number is expected to increase by 333 million by 2025. Type II diabetes is also known as non-insulin dependent diabetes // and is characterized by a relative disparity between endogenous insulin production and insulin requirements, leading to an elevated glucose. In contrast to Type I diabetes, there is always some endogenous insulin production, and many patients have normal or even elevated blood insulin levels. The disease usually occurs over the age of 40 and treatment involves diet, oral hypoglycemic drugs and exogenous insulin.

However, side effect profile of the given medication, route of administration or difficulties in sustaining glucose control pose serious concerns and necessitate more tolerable treatments that do not cause weight gain and produce less risk of hypoglycemia for patients with type 2 diabetes.

Clinical phase II studies involving Sitagliptin, an investigational diabetes drug, appears to control blood sugar with a low incidence of hypoglycaemia and with a neutral effect on body weight.

Sitagliptin is expected to lower blood glucose levels by increasing the level of active incretin hormones which increase insulin from pancreatic beta-cells and decrease glucagon from pancreatic alpha cells in a glucose-dependent manner (when blood glucose is elevated and not when blood glucose is low). If approved, Sitagliptin would be a member of a new class of antihyperglycaemic agents called DPP-IV inhibitors, which inhibit the DPP-4 enzyme that normally inactivates the incretin gut hormones GLP-1 and GIP. The patients studied exhibited a safety and tolerability profile similar to placebo. In addition, patients taking Sitagliptin experienced no significant weight gain and a low risk of hypoglycaemia. Patients treated with glipizide had an average weight gain of 1.1 kilogram relative to placebo. Adverse event reports of hypoglycaemia were observed in 4 percent of patients taking Sitagliptin, 17 percent of patients taking glipizide and 2 percent of patients taking placebo.

Results from the studies conducted to date are very promising and ongoing Phase III trials are expected to provide greater insight into the efficacy and tolerability profile of Sitagliptin over a longer period of time.


'"/>




Related medicine news :

1. Undertaking the obesity epidemic
2. Breast Cancer in Men Often Underestimated and Under-treated
3. Drug to Lower Cholesterol Underused
4. Understanding The Predictors Of Prostate Cancer
5. Understanding Restless Legs Syndrome
6. Understanding Lung Cancer Metastasis
7. Understanding The Link Between Hormone Replacement and Respiratory Disease
8. Understanding The Risks Of Hormone Therapy
9. Understanding The Link Between Metabolic Syndrome And Drinking Patterns
10. A Better Understanding Of The Brain Network
11. Understanding The Predictor’s Of Alzheimer’s Diseae
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... , ... June 24, 2016 , ... Finally, a bruise ... venous procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a ... procedures. , dermaka cream is very effective for bruising and causes a rapid ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Today, InhaleLabs.com ... the ingestion of their medication by matching users with high quality water pipes within ... pieces with no commitment. , Inhale was founded by two brothers, Nick and Mike ...
(Date:6/23/2016)... ... 23, 2016 , ... Terumo BCT, a global medical device ... transfusion research programs and for the blood supply in the Netherlands, today announced ... Rating Score (PREPAReS) study. , Currently in its sixth year, the PREPAReS ...
(Date:6/23/2016)... ... ... The Mechille Wilson Agency, a Texas-based insurance company that provides coverage to ... initiating a charity drive to assist a student to be chosen from the local ... will be presented to the chosen student to help with the growing costs of ...
(Date:6/23/2016)... ... 23, 2016 , ... Representatives of CHA Fertility Centers (CFC), one of the ... Dr. Joshua J. Berger. As of May 2016, Dr. Berger will serve as ... Berger has received recognition for his research, his teaching and his patient care. After ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
Breaking Medicine Technology: